<DOC>
	<DOCNO>NCT01546402</DOCNO>
	<brief_summary>This study undertaken determine effect intravitreal long act dexamethasone implant , ( Ozurdex® ) improve outcome cataract surgery patient diabetic macular edema . Diabetic Macular Edema cataract constitute important cause visual impairment patient diabetes . Cataract surgery patient diabetic retinopathy associate progression retinopathy . Several modality non-steroidal anti-inflammatory agent , carbonic anhydrase inhibitor , corticosteroid , hyperbaric oxygen , laser photocoagulation vitrectomy internal limit membrane peel try manage inflammatory cystoid macular edema . Intravitreal Triamcinolone Acetonide ( TA ) , water insoluble steroid , show reduce retinal thickness improve visual acuity . However , recurrence macular edema patient receive intravitreal TA major concern patient need multiple repeat injection . In search ideal corticosteroid preparation , Dexamethasone Posterior Segment Drug Delivery System ( Dexamethasone DDS - Ozurdex® , Allergan Inc , Irvine , California ) recently develop . Promising result show certain patient persistent diabetic macular edema receive intravitreal drug delivery system improvement visual acuity The present study introduces novel concept use intraoperative Ozurdex ® implant patient diabetes mellitus undergoing cataract surgery minimize worsen diabetic maculopathy .</brief_summary>
	<brief_title>Intraoperative Dexamethasone Implant Improves Outcome Cataract Surgery With Diabetic Macular Edema</brief_title>
	<detailed_description>Diabetic Macular Edema ( DME ) cataract constitute important cause visual impairment patient diabetes mellitus . Cataract surgery patient diabetic retinopathy associate progression retinopathy maculopathy nearly 23-57 % case , thus affect final visual outcome . Post-cataract surgery , macular edema may due worsening/presence pre-existing clinically significant macular edema ( CSME ) due development Irvine Gass Syndrome cystoid macular edema ( CME ) occur post operative period believe inflammatory origin . Focal/ grid laser photocoagulation standard care management CSME , may pre-existing time cataract surgery worsen follow surgery . Several adjunct include intravitreal corticosteroid , Pegaptanib Sodium ( Macugen ; Pfizer , New York ) , Ranibizumab ( Lucentis ; Genentech , South San Francisco , California ) , Bevacizumab ( Avastin , Genentech ) try attempt improve visual result . Several modality non-steroidal anti-inflammatory agent , carbonic anhydrase inhibitor , corticosteroid , hyperbaric oxygen , laser photocoagulation vitrectomy internal limit membrane peel try manage inflammatory cystoid macular edema13 . Intravitreal Triamcinolone Acetonide ( TA ) , water insoluble steroid , show reduce retinal thickness improve visual acuity14-16 . However , recurrence macular edema patient receive intravitreal TA major concern patient need multiple repeat injection short half life drug ( 18.6 day ) . A potent steroid , dexamethasone also try alternative TA macular edema ; however , short half life 3 hour prevents clinical application . In search ideal corticosteroid preparation , Dexamethasone Posterior Segment Drug Delivery System ( DDS ) - Ozurdex® , Allergan Inc , Irvine , California ) recently develop generate new interest molecule . It sustain release intravitreal implant contain 700µg dexamethasone approve US-FDA ( Food Drug Administration ) treatment macular edema retinal vein occlusion . Promising result show certain patient persistent diabetic macular edema receive intravitreal drug delivery system improvement visual acuity . The present study introduces novel concept use intraoperative Ozurdex ® implant patient diabetes mellitus undergoing cataract surgery minimize worsen diabetic maculopathy .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Homatropine</mesh_term>
	<criteria>The patient Type 2 Diabetes Mellitus fulfil follow inclusion criterion shall enrol study : 1 . Presence visually significant cataract require surgery ( grade ) 2 . Patients Nonproliferative Diabetic Retinopathy ( NPDR ) with/without clinically significant macular edema ( CSME ) 3 . Patients Proliferative Diabetic Retinopathy ( PDR ) with/without CSME proliferative component adequately treat laser photocoagulation . All patient fulfil criterion 1 2 3 shall enrol study . The patient either sex age 60 year would include study . The follow would exclusion criterion : Presence untreated proliferative diabetic retinopathy Patients history ocular hypertension glaucoma Presence associate condition may exacerbate macular edema , i.e . uveitis , retinal vein occlusion , neovascular glaucoma History use drug prostaglandin analogue , adrenaline nicotinic acid Patients postoperative medium haze pupillary nondilation allow good fundus photography , Fundus Fluorescein Angiography ( FFA ) Optical Coherence Tomography ( OCT ) . Patients develop intraoperative complication include posterior capsular rent , vitreous loss , zonular dehiscence , etc shall exclude study group</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>